Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal

Can-Fite BioPharma ( (CANF) ) just unveiled an update.

Can-Fite Sinks on Publication

Can-Fite BioPharma Ltd. (NYSE: CANF) shares were lower Tuesday. The Israeli-based company, a clinical-stage biotechnology ...

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market ...

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy

Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- ...